GlassScriptPhysician profile
Paul B Canale
NPI 1710973490
$609,308.13
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336K · 2020: $57.81 · 2021: $273K · 2022: $172.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $335,097.61 | 2019 | |
| Medtronic, INC. | $273,432.20 | 2021 | |
| Djo, LLC | $184.00 | 2019-2020 | |
| Precision Spine, INC. | $125.52 | 2019 | |
| Abbott Laboratories | $115.13 | 2022 | |
| Titan Spine, LLC | $107.35 | 2019 | |
| Si-Bone, INC. | $64.92 | 2019 | |
| Corelink, LLC | $45.04 | 2019 | |
| Cerapedics INC. | $44.53 | 2022 | |
| Biocomposites INC | $31.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.74 | 2019 | |
| Horizon Therapeutics Plc | $16.43 | 2020 | |
| Stryker Corporation | $14.09 | 2019 | |
| Zimvie INC. | $12.53 | 2022 |
Research and ownership
$726,562.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Canale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.